Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders

David Stein, Ernesto Oviedo-Orta, Wendy A. Kampman, Jennifer McGinnis, George Betts, Margaret McDermott, Beth Holly, Johnathan M. Lancaster, Ned Braunstein, George D. Yancopoulos, and David M. Weinreich

Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA

**Background.** Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection, having no viable treatment options.

**Methods.** A retrospective analysis of patients with primary and/or secondary immunodeficiency-associated antibody disorders who received casirivimab and imdevimab (REGEN-COV®) under emergency compassionate use. Objective were to describe safety and response to REGEN-COV, focusing on the subset of patients who had COVID-19 duration ≥21 days before treatment.

**Results.** Quantitative (change in oxygenation status and/or viral load) and/or qualitative (physician-reported clinical status) outcomes data are reported from 64 patients. Improvement in ≥1 outcome was observed in 90.6% of the overall patient group. Thirty-seven of these had COVID-19 duration ≥21 days before treatment; median time from diagnosis to REGEN-COV treatment was 60.5 days. Of the 29 patients with COVID-19 duration ≥21 days before treatment and available outcome data, 96.6% showed improvement in ≥1 outcome. In the 14 patients with post-treatment reverse transcription–polymerase chain reaction (RT-PCR) results available, 11 (78.6%) reported a negative RT-PCR following treatment, with 5 (45.5%) and 8 (72.7%) patients reporting a negative RT-PCR within 5 days and 21 days of treatment, respectively. Ten of 85 patients (11.8%) experienced serious adverse events; only one was an infusion-related reaction, possibly related to REGEN-COV. Two deaths were reported; neither were attributed to REGEN-COV.

**Conclusions.** In this retrospective analysis of immunodeficient patients granted REGEN-COV under emergency compassionate use, REGEN-COV treatment was associated with rapid viral clearance and clinical improvement in patients with longstanding COVID-19. Adverse events were consistent with COVID-19 and its associated complications, and due to patients’ concurrent medical conditions.

**Keywords.** antibody deficiency; B-cell deficiency; compassionate use; COVID-19; monoclonal antibody.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), first emerged in 2019, and has led to a global pandemic. Patients infected with SARS-CoV-2 are at risk of developing a range of respiratory conditions, from mild to severe symptoms, and sometimes fatal illness [1]. Patients with either primary or secondary immunodeficiency-associated antibody disorders who have an inherited or acquired inability to produce antibodies against infective agents have a high risk of suffering from prolonged or persistent SARS-CoV-2 infection, increasing their morbidity and mortality risk [2–4]. These patients are also likely to show lack of, or significantly less effective, protective immune responses to vaccines [5], and may have to rely on alternate prevention and treatment regimes.

The treatment of immunocompromised patients with COVID-19 using convalescent plasma is controversial due to a lack of specificity and variable content of potent neutralizing antibodies [6–8]. In February 2021, the US Food and Drug Administration (FDA) issued a revision of the Emergency Use Authorization for COVID-19 convalescent plasma, for the treatment of hospitalized patients with COVID-19 who have impaired humoral immunity and cannot produce an adequate antibody response [9]. However, results from 3 small randomized controlled trials in patients with moderate-to-severe COVID-19 showed no significant differences in improved clinical outcomes between the convalescent plasma-treated and placebo groups [10–12].

Casirivimab and imdevimab (REGEN-COV®; Regeneron Pharmaceuticals, Inc.) is a combination of 2 human,
immunoglobulin G1 monoclonal antibodies (mAbs) that bind the receptor-binding domain of the SARS-CoV-2 spike protein and block interaction with angiotensin-converting enzyme 2 [13]. REGEN-COV targets separate non-overlapping epitopes, thereby neutralizing SARS-CoV-2, with a reduced likelihood of viral escape due to genetic mutations [14]. Furthermore, this combination of mAbs has been shown to retain neutralization potency against multiple SARS-CoV-2 variants [14]. The blood levels of SARS-CoV-2 neutralizing activity that are achieved with REGEN-COV are approximately 10 000- to 100 000-fold higher than that achievable with high-titer convalescent plasma. Correspondingly, REGEN-COV has demonstrated convincing activity across multiple phase 2 and 3 studies and across the continuum of the disease, including pre- and post-exposure prophylaxis [15], as well as in the treatment of both outpatients and hospitalized patients [16–19]. Across these studies, the greatest benefit was observed in patients who had not yet developed their own adaptive immune response at baseline (ie, who did not make their own anti–SARS-CoV-2 antibodies and are thus termed “seronegative”); such high-risk seronegative patients may share characteristics with individuals with an immunodeficiency who cannot mount an antibody response.

Informed by the clinical data from the REGEN-COV program, Regeneron has, with the approval of the FDA, been granting compassionate use to patients with COVID-19 and primary and/or secondary immune deficiencies. This retrospective analysis of such patients who received REGEN-COV under emergency compassionate use gathered data to provide a better understanding of clinical outcomes in this vulnerable group. While data for all patients (the overall patient group) are presented, we give particular focus to the subset of patients with COVID-19 duration of 21 days or more prior to treatment, as this subset reflects those unable to effectively clear the virus.

METHODS

Analysis Overview
This is a retrospective, descriptive data analysis using de-identified patient data from patients who received REGEN-COV under emergency compassionate use from 2 September 2020 to 29 March 2021.

Patients were evaluated and eligible for REGEN-COV under compassionate use if they had a serious, life-threatening disease (where the patient cannot wait for the usual approval process), had sufficient evidence of a positive risk/benefit of using the experimental agent for the condition affecting the patient, were not eligible for any available clinical trial, and had no viable or available treatment options. To be eligible for compassionate use, patients had to have a positive SARS-CoV-2 reverse transcription–polymerase chain reaction (RT-PCR) within approximately 1 week of treatment. Each request for compassionate use was reviewed by the compassionate use committee consisting of senior leaders at Regeneron Pharmaceuticals, Inc., prior to submission to the FDA for approval. Requesting physicians in the United States had to obtain authorization from FDA for an emergency Investigational New Drug (IND) and comply with the requirements of 21 CFR 312.310; requests outside of the United States had to comply with all local regulations. Further information and details about the compassionate-use program can be found at https://www.regeneron.com/downloads/regeneron-compassionate-use-request.pdf.

Outcome Measures
The objective of this retrospective analysis was to describe safety and response to REGEN-COV in patients with primary and/or secondary immunodeficiency-associated antibody disorders who were evaluated and approved for drug use under compassionate use. Response to REGEN-COV is described using quantitative patient outcome data (change in oxygenation status and/or viral load) and/or qualitative patient outcome data (physician-reported clinical status). Serious adverse events (SAEs) and death were also evaluated.

Oxygenation status is described as oxygen requirement and correlated oxygen saturations. Viral load is described by either SARS-CoV-2 RT-PCR status (negative or positive) and/or cycle threshold (Ct) values in RT-PCR, prior to and after compassionate use of REGEN-COV. Descriptive safety data are also presented. Reporting of SAEs, adverse events of special interest (grade ≥2 infusion-related reactions, grade ≥2 hypersensitivity reactions), and pregnancy was a requirement for treatment under compassionate use.

Ethics
The treating physician was responsible for compliance in accordance with the principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements for administering an investigational product under compassionate use. The treating physician was also responsible for all safety reporting and regulatory obligations associated with the conduct of the compassionate use as required by applicable law. The institutional review board (WCG IRB, Puyallup, WA; IRB tracking number 20212896) found that this research met the requirements for a waiver of consent under 45 CFR 46.116(f) and 45 CFR 46.116(d). All patients provided written informed consent before receiving treatment.

RESULTS

Patients With COVID-19 Duration of ≥21 Days Prior to Treatment
In total, 174 patients from the United States were evaluated and approved to receive REGEN-COV under the emergency compassionate-use program as of 29 March 2021, of whom 95 (54.6%) had primary and/or secondary immunodeficiency-associated antibody disorders. Of these patients, 85 received...
intravenous REGEN-COV and data are available for 64 of these patients. Of the 64 patients with available data, 37 (43.5%) had COVID-19 duration of 21 days or more prior to treatment.

In the subset of patients with COVID-19 duration of 21 days or more prior to treatment, 64.9% were male, the mean age was 49.1 years (median: 52.0 years; minimum–maximum [min–max]: 1–75 years), 27.0% were aged 65 years or older, and 27 of 37 (73.0%) were inpatients. The median time from RT-PCR diagnosis to administration of REGEN-COV was 60.5 days (min–max: 25–218 days; mean: 83.2 days). Three patients (8.1%) had primary immunodeficiency-associated antibody disorders, and 34 patients (91.9%) had secondary causes of immunodeficiency-associated antibody disorders (malignant or drug induced); the most common causes included treatment with anti-CD20 (rituximab), acute lymphocytic leukemia, follicular lymphoma, diffuse B-cell lymphoma, and other non-Hodgkin’s lymphomas (Table 1).

Of the 37 patients with COVID-19 duration of 21 days or more prior to treatment, qualitative or quantitative outcome data were available for 29 patients: 23 (79.3%) had qualitative physician assessment at follow-up, 22 (75.9%) had oxygenation status measured, and 14 (48.3%) had secondary causes of immunodeficiency-associated antibody disorders (malignant or drug induced); the most common causes included treatment with anti-CD20 (rituximab), acute lymphocytic leukemia, follicular lymphoma, diffuse B-cell lymphoma, and other non-Hodgkin’s lymphomas (Table 1).

Overall Patient Group
In the overall patient group, 62.4% were male, the mean age was 47.4 years (median: 52.0 years; min–max: 1–79 years), 24.7% of patients were aged 65 years or older, and the majority were inpatients (65/85; 76.5%). The median time from RT-PCR diagnosis to administration of REGEN-COV was 13.0 days (min–max: 1–218 days; mean: 40.8 days). Thirteen patients (15.3%) had primary (genetic) immunodeficiency-associated antibody disorders, and 14 of 64 (21.9%) had secondary causes of immunodeficiency-associated antibody disorders (malignant or drug-induced) (Supplementary Table 1).

Table 1. Reverse Transcription–Polymerase Chain Reaction Outcomes by Disease Diagnosis in the Subset of Patients With Disease Duration ≥21 Days Prior to Treatment

| Disease Diagnosis                                      | Total | RT-PCR Negative | RT-PCR Positive | RT-PCR Unknown |
|-------------------------------------------------------|-------|-----------------|-----------------|----------------|
| Primary B-cell (genetic) immunodeficiencies<sup>a</sup> | 3     | ...             | ...             | 3              |
| Common variable immunodeficiency                      | 2     | ...             | ...             | 2              |
| X-linked agammaglobulinemia                           | 1     | ...             | ...             | 1              |
| Secondary causes of B-cell deficiency (malignant or drug-induced)<sup>b</sup> | 34    | 11              | 3               | 20             |
| Treatment with anti-CD20—rituximab                    | 12    | 5               | 1               | 6              |
| Acute lymphocytic leukemia                            | 7     | 3               | ...             | 4              |
| Follicular lymphoma                                   | 6     | 2               | ...             | 4              |
| Diffuse B-cell lymphoma                               | 5     | 1               | 2               | 2              |
| Non-Hodgkin’s lymphoma                                | 5     | 1               | ...             | 4              |
| Transplant<sup>c</sup>                                | 3     | 1               | ...             | 2              |
| Chronic lymphoid leukemia                             | 2     | 1               | ...             | 1              |
| Burkitt’s lymphoma                                    | 2     | 1               | ...             | 1              |
| Mantle cell lymphoma                                  | 2     | 1               | 1               | ...            |
| Treatment with methotrexate                           | 1     | 1               | ...             | ...            |
| Chronic immunosuppression for treatment of IgA nephropathy | 1     | ...             | ...             | 1              |

Data presented is number of patients. Abbreviations: IgA, immunoglobulin A; RT-PCR, reverse transcription-polymerase chain reaction.

<sup>a</sup>Patients may report more than 1 condition.

<sup>b</sup>The types of transplant were as follows: stem cell, 2 patients; lung, 1 patient.
1 week prior to and after compassionate use of REGEN-COV. Overall, 90.6% of patients (58/64; 95% CI: 80.1–96.1%) showed improvement in 1 or more of these measures following compassionate use of REGEN-COV. Qualitative physician follow-up showed that 52 of 58 patients (89.7%; 95% CI: 78.2–95.7%) had improved. A total of 33 of 39 patients (84.6%; 95% CI: 68.8–93.6%) had an improved oxygenation status, either increased oxygen saturation or reduced oxygen requirement (Supplementary Figure 1) and 14 of 14 of patients (100%; 95% CI: 89.1–100%) had improved Ct on a post–baseline RT-PCR (Figure 3).

All 14 patients with a quantitative RT-PCR assessment showed rapid reduction in viral load with REGEN-COV treatment despite having a diagnosis of immunodeficiency (as shown by an increase in cycle time in Figure 3). Qualitative RT-PCR was evaluable in 28 patients from the overall patient group, and 20 (71.4%) of these reported a negative RT-PCR post-baseline; 3 additional patients had a fluctuating negative RT-PCR test. RT-PCR outcomes by disease diagnosis in the overall patient group are summarized in Supplementary Table 1.

**Safety**

In the overall patient group, 10 of 85 patients (11.8%) experienced SAEs (as defined by physician completion of an SAE form), of which only 1 event was an infusion-related reaction judged as possibly related to REGEN-COV. No other SAEs were
judged as being possibly related to treatment with REGEN-COV. Two patients who experienced SAEs had a COVID-19 duration of 21 days or more prior to treatment. There were 2 deaths reported, neither of which were attributed by the investigator to treatment with REGEN-COV: 1 from hypoxia and 1 from respiratory failure secondary to chronic COVID-19 and diffuse alveolar hemorrhage complicated by pulmonary aspergillosis. The events reported were consistent with COVID-19 and its associated complications and due to patients' concurrent medical conditions.

DISCUSSION

Because immunocompromised patients cannot generate their own antibodies against SARS-CoV-2, whether by vaccination or natural infection, they represent a particularly vulnerable and high-risk population. Antibody-related treatments for SARS-CoV-2—compensating for the lack of endogenous antibodies—are potentially viable treatment options, including polyclonal antibodies such as convalescent plasma [20]. However, the available clinical data have shown no efficacy in patients with COVID-19 when treated with convalescent plasma [10–12], which generally has limited amounts of SARS-CoV-2 neutralizing antibody levels. In contrast, 10 000–100 000-fold higher levels of neutralizing activity can be achieved with recombinant antibody treatments such as REGEN-COV, which has demonstrated convincing activity across multiple phase 2 and 3 studies and across the continuum of the disease, including in high-risk seronegative patients who share some characteristics with individuals with an immunodeficiency who cannot mount an antibody response [15–19].

Case reports have demonstrated treatment benefit with REGEN-COV in individual patients with primary and/or secondary immunodeficiencies, either alone or in combination with standard-of-care antiviral therapies [21–25]. Furthermore, in a report of 25 solid-organ-transfer outpatients with mild-to-moderate COVID-19, no patient experienced symptom progression or required hospitalization following treatment with REGEN-COV [24]. Additionally, in a case report of a kidney transplant recipient with COVID-19 following poor response to vaccination, treatment with REGEN-COV led to seroconversion and improved clinical and virologic outcomes [26]. It is important to note that a third mRNA vaccination may improve the humoral response in some transplant patients [27], and that additional vaccination may obviate the need for REGEN-COV in these patients. REGEN-COV treatment should not be utilized in place of vaccination but rather as an alternative approach in those who show continued poor response to vaccination.

As far as we are aware, this is the first report describing outcomes following REGEN-COV treatment for COVID-19 in a series of patients with primary and/or secondary immunodeficiency-associated antibody disorders. In this retrospective analysis, 96.6% of patients with COVID-19 duration of 21 days or more prior to treatment showed marked improvement in 1 or more qualitative and/or quantitative outcomes following compassionate use with REGEN-COV, with 85.7% showing improvement within 7 days of treatment. Most patients with evaluable RT-PCR data during follow-up showed rapid reductions in viral load, despite many having prolonged duration of infection prior to administration of REGEN-COV.

It is, however, important to interpret the data presented in context. The majority of patients in this report were treated before vaccines were widely available, and before antibody testing was widely utilized. Furthermore, given that this is a case series of patients treated under compassionate use, and not a clinical trial, there is no comparator group and we cannot account for bias. Additionally, there was no standard of practice on when
to repeat PCR post-treatment, nor were there prespecified data-collection parameters. We can therefore only report results based on the data captured at the discretion of the treating physician.

This case series provides data that are consistent with the totality of the data from phase 2 and 3 studies of REGEN-COV [15–19], in which the greatest benefit with REGEN-COV was seen in high-risk patients who had not yet mounted their own antibody response, and thus may share some characteristics consistent with immunodeficient patients. In those studies, REGEN-COV treatment in those who had not yet mounted their own immune response was associated with robust and rapid reduction in viral load as well as improvement in clinical outcome measures. The data from this case series describe high recovery rates comparable to those in the phase 2 and 3 studies who had not yet mounted an immune response.

In some countries, REGEN-COV is approved for the treatment and prevention of COVID-19 broadly. However, in the United States, the current authorization for treatment with REGEN-COV only covers recently diagnosed patients (within 10 days of symptom onset) [28] and thus would not allow for treatment of these immunocompromised patients with longstanding disease or who are hospitalized. In this retrospective analysis of patients with COVID-19 with primary and/or secondary immunodeficiency-associated antibody disorders who were granted REGEN-COV under the compassionate-use program, the majority showed rapid clinical improvement and viral clearance following treatment with REGEN-COV. These data, along with the previously reported clinical trial data, support the broader use of REGEN-COV for the treatment and prevention of COVID-19 in the immunocompromised patient population.

Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes
Acknowledgments. The authors thank the patients, their families, and the physicians involved in this work, as well as Caryn Tribovic, PhD, from Regeneron Pharmaceuticals, Inc. for medical writing support, and Prime, Knutsford, UK, for formatting and copy-editing suggestions and for assistance with the development of the manuscript.

Financial support. This work was supported by Regeneron Pharmaceuticals, Inc.

Potential conflicts of interest. D. S., E. O.-O., W. A. K., J. M., G. B., M. M., B. H., J. M. L., N. B., and D. M. W. are Regeneron Pharmaceuticals, Inc. employees/stockholders. G. D. Y. is a Regeneron Pharmaceuticals, Inc. employee/stockholder and has issued patents (US patent numbers 10787501, 10954289, and 10975139) and pending patents, which have been licensed and are receiving royalties, with Regeneron Pharmaceuticals, Inc. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061–9.
2. He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia 2020; 34:1637–45.
3. Hueso T, Poudreux C, Pere H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 2020; 136:2290–5.
4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–4.
5. Righi E, Gallo T, Azzini AM, et al. A review of vaccinations in adult patients with secondary immunodeficiency. Infect Dis Ther 2021; 10:637–61.
6. Devarasetti PK, Rajaeshekar L, Basiy R, Sreejitha KS, Vardhan YK. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy. Immunol Res 2021; 69:18–25.
7. Janiaud P, Axford C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA 2021; 325:1185–95.
8. Katz LM. (A little) clarity on convalescent plasma for Covid-19. N Engl J Med 2021; 384:666–8.
9. Food and Drug Administration. Emergency use authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). Available at: https://www.fda.gov/media/141478/download. Accessed 30 July 2021.
10. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371:m3939.
11. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomised controlled trial. JAMA 2020; 324:460–70.
12. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021; 384:619–28.
13. Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020; 369:1010–4.
14. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutual escape seen with individual antibodies. Science 2020; 369:1014–8.
15. O’Brien MP, Forles-Noet E, Musser BJ, et al. Subcutaneous REGN-COV antibody combination to prevent Covid-19. N Engl J Med 2021; 385:1184–95.
16. RECOVERY Collaborative Group; Horby PW, Mamh M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv, 2021, preprint: not peer reviewed. Available at: https://doi.org/10.1101/2021.06.15.21258542.
17. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV-1 antibody cocktail in outpatients with Covid-19. medRxiv, 2021, preprint: not peer reviewed. Available at: https://doi.org/10.1101/2021.06.09.21257915.
18. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021; 384:238–51.
19. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med 2021; 385:e81.
20. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211:80–90.
21. Drouin AC, Theberge MW, Liu SY, et al. Successful clearance of 300 day SARS-CoV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) COVID by REGN-COV anti-spike monoclonal antibody cocktail. Viruses 2021; 13:1202.
22. Luillet F, Vais D, Gidron A. Successful treatment of persistent coronavirus disease 2019 infection in a patient with hypogammaglobulinemia with REGN-COV2: a case report. Open Forum Infect Dis 2021; 8:oofab335.
23. Palomba E, Carrabba M, Zaglia G, et al. Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinemia. Int J Infect Dis 2021; 110:338–40.
24. Dhand A, Lobo SA, Wolfe K, et al. Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience. Transplantation 2021; 105:e68–9.
25. Ahearn AJ, Maw TT, Mehta R, et al. A programmatic response, including bamlanivimab or casirivimab-imdevimab administration, reduces hospitalization and death in COVID-19 positive abdominal transplant recipients. Transplantation 2021; doi:10.1097/TP.0000000000003953.

26. De Greef J, Devresse A, Saad Albichr I, et al. Better late than never: eventual seroconversion against SARS-CoV-2 in a kidney transplant recipient after repeated immune challenge and monoclonal antibody therapy. Kidney Int 2021; 100:1131–2.

27. Masset C, Kerleau C, Garandeau C, et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. Kidney Int 2021; 100:1132–5.

28. US Food and Drug Administration. Fact sheet for health care providers. Emergency Use Authorization (EUA) of REGEN-COV® (casirivimab and imdevimab). Available at: https://www.fda.gov/media/145611/download. Accessed 24 June 2021.